Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer, Including Non-small-cell Lung Cancer and Small-cell Lung Cancer With Early and Advanced Staging

NCT06975384 is registered in ClinicalTrials.gov with Second Xiangya Hospital of Central South University as lead sponsor.

NCT NCT06975384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06975384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer, Including Non-small-cell Lung Cancer and Small-cell Lung Cancer With Early and Advanced Staging
Lead sponsor
Second Xiangya Hospital of Central South University
Phase
Observational
Overall status
Recruiting
Start date
November 1, 2024
Completion date
December 31, 2030
Enrollment
1,270 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, treatment-related, immune checkpoint inhibitors, lung cancer, sleep disturbance